Multiple Sebaceous Adenomas and Extraocular Sebaceous Carcinoma in a Patient with Multiple Sclerosis: Case Report and Review of Literature

2001 ◽  
Vol 5 (6) ◽  
pp. 490-495 ◽  
Author(s):  
Saad Akhtar ◽  
Krishna K. Oza ◽  
Randolph G. Roulier
2018 ◽  
Vol 175 ◽  
pp. 134-136 ◽  
Author(s):  
G.T. Maniscalco ◽  
I. Cerillo ◽  
G. Servillo ◽  
M. Napolitano ◽  
G. Guarcello ◽  
...  

2001 ◽  
Vol 5 (6) ◽  
pp. 490-495 ◽  
Author(s):  
Saad Akhtar ◽  
Krishna K. Oza ◽  
Randolph G. Roulier

Background: Sebaceous carcinomas are relatively rare cutaneous tumors; there are fewer than 600 cases reported. They most commonly arise within the meibomian gland of the eyelid; fewer than 150 of the reported cases were extraocular. These tumors have a high incidence of local recurrence and regional metastasis. The relationship of sebaceous tumors and visceral malignancy is well established in the literature. Objective: We describe a 44-year-old white female with chronic progressive multiple sclerosis who developed multiple scalp sebaceous adenomas and a solitary sebaceous carcinoma. Conclusion: Extraocular sebaceous carcinomas are rare tumors with high incidence of local recurrence and regional metastasis. Surgery with wide surgical margins is the standard treatment. We report the first case of multiple sebaceous tumors in a patient with multiple sclerosis. The presence of sebaceous tumors warrants a search for an internal malignancy. Literature on sebaceous tumors and their relationship with visceral malignancies and immunologic disorders is discussed. Literature on sebaceous carcinoma with special attention to extraocular sebaceous carcinoma is also discussed.


Author(s):  
Antonio Arlindo Morais ◽  
José Wagner Leonel Tavares Júnior ◽  
Antônio Pinto De Melo Neto ◽  
Francisco Pitombeira Lima ◽  
Carlos Augusto Ciarline Teixeira ◽  
...  

Objetivo: Relatar o caso de um paciente com recidiva de herpes-zoster (HZ) e evolução benigna mesmo diante de imunomodulação para esclerose múltipla (EM). Descrição de caso: Mulher de 48 anos com história de EM durante seis anos, previamente tratada com interferon1b, iniciou tratamento com fingolimode, desenvolvendo HZ após 10 meses de tratamento. Mesmo sem tratamento com acyclovir, a paciente desenvolveu um curso brando, sem posterior desenvolvimento de neuralgia pós-herpética. Conclusões: As novas terapias para EM podem estar associadas a novos tipos de eventos adversos. Apesar da potencial gravidade, nem todos os pacientes com HZ em uso das novas terapias para EM têm curso desfavorável, sendo necessários estudos para identificar fatores de risco para as formas graves.


Sign in / Sign up

Export Citation Format

Share Document